Source Characterization and Pretreatment Evaluation Of
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Nature, Frequency and Determinants of Prescription Modifications in Dutch
Nature, frequency and determinants of prescription modi®cations in Dutch community pharmacies Henk Buurma,1,3 Peter A. G. M. de Smet,2,5 Olga P. van den Hoff2 & Antoine C. G. Egberts3,4 1SIR Institute for Pharmacy Practice Research, Leiden, 2WINAp (Scienti®c Institute Dutch Pharmacists), The Hague, 3Department of Pharmacoepidemiology and Pharmacotherapy, Faculty of Pharmacy, University of Utrecht, 4Hospital pharmacy `Midden-Brabant', TweeSteden Hospital and St Elisabeth Hospital, Tilburg and 5Department of Clinical Pharmacy, University Hospital Nijmegen, The Netherlands Aims To examine the nature, frequency and determinants of prescription modi®cations in Dutch community pharmacies. Methods A prospective case-control study comparing modi®ed prescriptions with nonmodi®ed prescriptions was carried out in 141 Dutch community pharmacies. 2014 modi®ed prescriptions (cases), collected in the selected pharmacies on a predetermined day in a speci®c period (25th February until 12th March 1999) and 2581 nonmodi®ed prescriptions (controls) randomly selected on the same day were studied. The nature and frequency of prescription modi®cations and patient, drug and prescriber related determinants for a modi®ed prescription were assessed. Results The overall incidence of prescription modi®cations was 4.3%, with a mean of 14.3 modi®cations per pharmacy per day. For prescription only medicines (POM) the incidence was 4.9%. The majority of POM modi®cations concerned a clari®cation (71.8%). In 22.2% a prescription could potentially have had clinical consequences when not altered; in more than half of the latter it concerned a dose error (13.7% of all cases). POM prescriptions of patients of 40±65 years had a signi®cantly lower chance of modi®cation compared with those of younger people (OR=0.74 [0.64±0.86]). -
Glypressin Ferring Pharmaceuticals Pty Ltd PM-2010-03182-3-3 Final 26 November 2012
Attachment 1: Product information for AusPAR Glypressin Ferring Pharmaceuticals Pty Ltd PM-2010-03182-3-3 Final 26 November 2012. This Product Information was approved at the time this AusPAR was published. Product Information ® GLYPRESSIN Solution for Injection NAME OF THE MEDICINE Terlipressin (as terlipressin acetate). The chemical name is N-[N-(N-Glycylglycyl)glycyl]-8-L- lysinevasopressin. Terlipressin has an empirical formula of C52H74N16O15S2 and a molecular weight of 1227.4. CAS No: 14636-12-5. The pKa is approximately 10. Terlipressin is freely soluble in water. Although the active ingredient is terlipressin, the drug substance included in this product contains non-stoichiometric amounts of acetic acid and water, and this material is freely soluble in water. The structural formula of terlipressin is DESCRIPTION GLYPRESSIN is for intravenous injection. It consists of a clear, colourless liquid containing 0.85 mg terlipressin (equivalent to 1 mg terlipressin acetate) in 8.5 mL solution in an ampoule. The concentration of terlipressin is 0.1 mg/mL (equivalent to terlipressin acetate 0.12 mg/mL). List of excipients GLYPRESSIN contains the following excipients: Sodium chloride, acetic acid, sodium acetate trihydrate, Water for Injections PHARMACOLOGY Pharmacodynamics Terlipressin belongs to the pharmacotherapeutic group: Posterior pituitary lobe hormones (vasopressin and analogues), ATC code: H 01 BA 04. Terlipressin is a dodecapeptide that has three glycyl residues attached to the N-terminal of lysine vasopressin (LVP). Terlipressin acts as a pro-drug and is converted via enzymatic cleavage of its three glycyl residues to the biologically active lysine vasopressin. A large body of evidence has consistently shown that terlipressin given at doses of 0.85 mg and 1.7 mg respectively (equivalent to terlipressin acetate 1 mg and 2 mg respectively) can effectively reduce the portal venous pressure and produces marked vasoconstriction. -
ZOMACTON Powder and Solvent for Solution for Injection 4Mg Package
NAME OF THE MEDICINAL PRODUCT Intra‑cranial lesions or other active neoplasms ZOMACTON® 4 mg, powder and solvent for solution for injection In patients with growth hormone deficiency secondary to an intra‑cranial lesion, frequent QUALITATIVE AND QUANTITATIVE COMPOSITION monitoring for progression or recurrence of the underlying disease process is advised. In One vial of powder contains: Somatropin* 4 mg childhood cancer survivors, an increased risk of a second neoplasm has been reported in (corresponding to a concentration of 1.3 mg/ml or 3.3 mg/ml after reconstitution) patients treated with somatropin after their first neoplasm. Intracranial tumours, in particular meningiomas, in patients treated with radiation to the head for their first neoplasm, were the * Produced in Escherichia coli cells using recombinant DNA technology most common of these second neoplasms. List of excipients: Discontinue ZOMACTON® therapy if progression or recurrence of the lesion occurs. Powder: Mannitol Solvent: Sodium chloride, benzyl alcohol, water for injections In patients with previous malignant diseases special attention should be given to signs and symptoms of relapse. PHARMACEUTICAL FORM Powder and solvent for solution for injection, 4 mg Scoliosis ZOMACTON® is a white to off‑white lyophilised powder. Scoliosis may progress in any child during rapid growth. Signs of scoliosis should be monitored The solvent in ampoule is clear and colourless. during somatropin treatment. THERAPEUTIC INDICATIONS Slipped capital femoral epiphysis ® Slipped capital femoral epiphysis may occur more frequently in patients with endocrine ZOMACTON is indicated for: ® - the long‑term treatment of children who have growth failure due to inadequate secretion disorders. A patient treated with ZOMACTON who develops a limp or complains of hip or of growth hormone knee pain should be evaluated by a physician. -
Rapport 2008
rapport 2008 Reseptregisteret 2004-2007 The Norwegian Prescription Database 2004-2007 Marit Rønning Christian Lie Berg Kari Furu Irene Litleskare Solveig Sakshaug Hanne Strøm Rapport 2008 Nasjonalt folkehelseinstitutt/ The Norwegian Institute of Public Health Tittel/Title: Reseptregisteret 2004-2007 The Norwegian Prescription Database 2004-2007 Redaktør/Editor: Marit Rønning Forfattere/Authors: Christian Lie Berg Kari Furu Irene Litleskare Marit Rønning Solveig Sakshaug Hanne Strøm Publisert av/Published by: Nasjonalt folkehelseinstitutt Postboks 4404 Nydalen NO-0403 Norway Tel: + 47 21 07 70 00 E-mail: [email protected] www.fhi.no Design: Per Kristian Svendsen Layout: Grete Søimer Acknowledgement: Julie D.W. Johansen (English version) Forsideillustrasjon/Front page illustration: Colourbox.com Trykk/Print: Nordberg Trykk AS Opplag/ Number printed: 1200 Bestilling/Order: [email protected] Fax: +47-21 07 81 05 Tel: +47-21 07 82 00 ISSN: 0332-6535 ISBN: 978-82-8082-252-9 trykt utgave/printed version ISBN: 978-82-8082-253-6 elektronisk utgave/electronic version 2 Rapport 2008 • Folkehelseinstituttet Forord Bruken av legemidler i befolkningen er økende. En viktig målsetting for norsk legemiddelpolitikk er rasjonell legemiddelbruk. En forutsetning for arbeidet med å optimalisere legemiddelbruken i befolkningen er kunnskap om hvilke legemidler som brukes, hvem som bruker legemidlene og hvordan de brukes. For å få bedre kunnskap på dette området, vedtok Stortinget i desember 2002 å etablere et nasjonalt reseptbasert legemiddelregister (Reseptregisteret). Oppgaven med å etablere registeret ble gitt til Folkehelseinstituttet som fra 1. januar 2004 har mottatt månedlige opplysninger fra alle apotek om utlevering av legemidler til pasienter, leger og institusjoner. Denne rapporten er første utgave i en planlagt årlig statistikk fra Reseptregisteret. -
New Zealand Data Sheet 1 Avaxim Suspension for Injection 2 Qualitative and Quantitative Composition 3 Pharmaceutical Form 4 Clin
NEW ZEALAND DATA SHEET 1 AVAXIM SUSPENSION FOR INJECTION Hepatitis A virus (inactivated, adsorbed) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Avaxim is a sterile suspension for injection containing formaldehyde-inactivated hepatitis A virus (GBM strain) adsorbed onto aluminium hydroxide. Each 0.5mL dose contains: Active ingredient: Hepatitis A virus* ………………………………………………160 antigen units** * GBM strain cultured on MRC-5 human diploid cells. MRC-5 is a cell line that was derived from human embryonic lung tissue in the 1960s. ** In the absence of an international standardised reference, the antigen content is expressed using an in-house reference. The manufacture of this product includes exposure to bovine derived materials. No evidence exists that any case of vCJD (considered to be the human form of bovine spongiform encephalopathy) has resulted from the administration of any vaccine product. Contains phenylalanine and residual neomycin. For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Suspension for injection Avaxim is a cloudy, whitish suspension. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Avaxim is indicated for active immunisation against hepatitis A infection in adults and children 2 years and over. Vaccination against viral hepatitis A is recommended for individuals who are or will be at increased risk of infection: • travellers to areas of moderate or high endemicity for hepatitis A Property of the Sanofi group - strictly confidential ava-ccdsv10-dsv5-24may21 Page 1 • visitors to rural and remote indigenous communities • child day-care and pre-school personnel • the intellectually disabled and their carers • health care providers • sewerage workers • men who have sex with men • injecting drug users • patients with chronic liver disease • haemophiliacs who may receive pooled plasma concentrates 4.2 DOSE AND METHOD OF ADMINISTRATION The dose is 0.5 mL for each injection. -
Elif Fatma Sen BW.Indd
Use and Safety of Respiratory Medicines in Children E. F. Şen EEliflif FFatmaatma SSenen BBW.inddW.indd 1 003-01-113-01-11 115:175:17 The work presented in this thesis was conducted at the Department of Medical Informatics of the Erasmus University Medical Center, Rotterdam. The research reported in thesis was funded by the European Community’s 6th Framework Programme. Project number LSHB-CT-2005-005216: TEDDY: Task force in Europe for Drug Development for the Young. The contributions of the participating primary care physicians in the IPCI, Pedianet and IMS-DA project are greatly acknowledged. Financial support for printing this thesis was kindly provided by the department of Medical Informatics – Integrated Primary Care Information (IPCI) project of the Erasmus University Medi- cal Center; and by the J.E. Jurriaanse Stichting in Rotterdam. Cover: Optima Grafi sche Communicatie Printed by: Optima Grafi sche Communicatie Elif Fatma Şen Use and Safety of Respiratory medicines in Children ISBN: 978-94-6169-003-6 © E.F. Şen, Rotterdam, the Netherlands, 2011. All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior written permission of the holder of the copyright. EEliflif FFatmaatma SSenen BBW.inddW.indd 2 003-01-113-01-11 115:175:17 Use and Safety of Respiratory Medicines in Children Het gebruik en de bijwerkingen van respiratoire medicijnen in kinderen Proefschrift Ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnifi cus Prof.dr. -
Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patien
1 2 3 PROJECT TITLE 4 Anti-viral Prophylaxis for Prevention of Cytomegalovirus (CMV) Reactivation in Immunocompetent 5 Patients in Critical Care 6 7 STUDY ACRONYM 8 Cytomegalovirus Control in Critical Care - CCCC 9 10 APPLICANTS 11 Dr Nicholas Cowley 12 Specialty Registrar Anaesthesia and Intensive Care Medicine, Intensive Care Research Fellow 13 Queen Elizabeth Hospital Birmingham 14 15 Professor Paul Moss 16 Professor of Haematology 17 Queen Elizabeth Hospital Birmingham 18 19 Professor Julian Bion 20 Professor of Intensive Care Medicine 21 Queen Elizabeth Hospital Birmingham 22 23 Trial Virologist Trial Statistician 24 Dr H Osman Dr P G Nightingale 25 Queen Elizabeth Hospital Birmingham University of Birmingham CCCC CMV Protocol V1.7, 18th September 2013 1 Downloaded From: https://jamanetwork.com/ on 09/23/2021 26 CONTENTS 27 Substantial Amendment Sept 18th 2013 4 28 1 SUMMARY OF TRIAL DESIGN .......................................................................................................... 5 29 2 QEHB ICU Duration of Patient Stay ................................................................................................. 6 30 3 SCHEMA - QEHB PATIENT NUMBERS AVAILABLE FOR RECRUITMENT ........................................... 6 31 4 INTRODUCTION ............................................................................................................................... 7 32 4.1 CMV latent infection is widespread ........................................................................................ 7 33 4.2 CMV Reactivation -
Respiratory Medication Use in Australia 2003–2013
This report describes patterns of dispensing of respiratory medications in Australia through detailed analyses of Respiratory medication use in Australia Pharmaceutical Benefits Scheme (PBS) data, as well as other sources, to draw inferences about respiratory 2003–2013 medication use among patients with asthma and COPD. It provides a valuable update and new information Treatment of asthma and COPD about the use of medicines for asthma and COPD, thus improving our knowledge and understanding about how these diseases are managed in Australia. ACAM Australian Centre for Airways disease Monitoring Respiratory medication use in Australia 2003–2013 Treatment of asthma and COPD Australian Institute of Health and Welfare Canberra Cat. no. ACM 31 The Australian Institute of Health and Welfare is a major national agency which provides reliable, regular and relevant information and statistics on Australia’s health and welfare. The Institute’s mission is authoritative information and statistics to promote better health and wellbeing. © Australian Institute of Health and Welfare and Woolcock Institute of Medical Research Limited 2015 This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 3.0 (CC-BY 3.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties. You may distribute, remix and build upon this work. However, you must attribute the AIHW as the copyright holder of the work in compliance with our attribution policy available at <www.aihw.gov.au/copyright/>. -
ATC) Classification and the Defined Daily Dose (DDD
Anatomical Therapeutic Chemical (ATC) classification T and the Defined Daily Dose AF DR (DDD): principles for classifying and quantifying drug use Yong Chen Merck, Whitehouse Station, NJ USA Disclosure • Author is an employee of Merck • A lot of slides are adopted from a prior ICPE English short course on drug utilization by Hege Salvesen Blix 2 Outline • The ATC/DDD methodology – definitions, purpose, structure and principles • Real world applications of ATC/DDD 3 What is ATC/DDD? • ATC (Anatomical Therapeutic Chemical) classification –Don’t confuse it with Anatomical Therapeutic (AT) classification developed by European Pharmaceutical Market Research Association (EPhMRA) • DDD (Defined Daily Dose) The assumed average maintenance dose per day for a drug used for its main indication in adults Introduction to Drug Utilization Research, WHO 2003 4 Main Purpose • “International language for drug utilization research” –to serve as a tool for presenting drug utilization research in order to improve quality of drug use –to compare data within a country and between countries 5 The WHO Collaborating Centre for Drug Statistics Methodology • Established in 1982 as a European WHO Centre • Since 1996 a global WHO Centre • Located in the Department of Pharmacoepidemiology at the Norwegian Institute of Public Health • The staff of the Centre is responsible for drug consumption statistics in Norway 6 The WHO Centre • To classify drugs according to the ATC system and assign DDDs • To review and revise as necessary the ATC classification system and DDDs • To stimulate and influence the practical use of the ATC system • To organize training courses in the ATC/DDD methodology 7 ATC Main Group • A Alimentary tract and metabolism • B Blood and blood forming organs • C Cardiovascular system • D Dermatologicals • G Genito urinary system and sex hormones • H Systemic hormonal preparations, excl. -
Modul 2(Pdf 551,29
Dokumentvorlage, Version vom 20.01.2011 Dossier zur Nutzenbewertung gemäß § 35a SGB V Pixantron (Pixuvri®) CTI Life Sciences Ltd. Modul 2 Allgemeine Angaben zum Arzneimittel, zugelassene Anwendungsgebiete Stand: 20.11.2012 Dossier zur Nutzenbewertung – Modul 2 Stand: 20.11.2012 Allgemeine Angaben zum Arzneimittel, zugelassene Anwendungsgebiete Inhaltsverzeichnis Seite Tabellenverzeichnis .................................................................................................................. 2 Abbildungsverzeichnis ............................................................................................................. 3 Abkürzungsverzeichnis ............................................................................................................ 4 2 Modul 2 – allgemeine Informationen ............................................................................ 7 2.1 Allgemeine Angaben zum Arzneimittel ....................................................................... 7 2.1.1 Administrative Angaben zum Arzneimittel ............................................................ 7 2.1.2 Angaben zum Wirkmechanismus des Arzneimittels ............................................... 8 2.2 Zugelassene Anwendungsgebiete ............................................................................... 34 2.2.1 Anwendungsgebiete, auf die sich das Dossier bezieht .......................................... 34 2.2.2 Weitere in Deutschland zugelassene Anwendungsgebiete ................................... 34 2.2.3 Zulassungsstatus international -
Caspofungin II-02
ANNEX I ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Caspofungin MSD 50 mg Powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 50 mg Caspofungin equivalent to 55.5 mg caspofungin acetate. For excipients, see 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for infusion. The vial contains a white to off-white compact, lyophilised powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications · Treatment of invasive candidiasis in non-neutropaenic adult patients. · Treatment of invasive aspergillosis in adult patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. 4.2 Posology and method of administration Caspofungin MSD should be initiated by a physician experienced in the management of invasive fungal infections. After reconstitution and dilution, the solution should be administered by slow intravenous infusion over approximately 1 hour. Do not mix or co-infuse Caspofungin MSD with other medicines, as there are no data available on the compatibility of Caspofungin MSD with other intravenous substances, additives, or medicinal products. DO NOT USE DILUENTS CONTAINING GLUCOSE, as Caspofungin MSD is not stable in diluents containing glucose. For reconstitution directions see section 6.6. Both 70 mg and 50 mg vials are available. Invasive Candidiasis or Invasive Aspergillosis: A single 70-mg loading dose should be administered on Day-1, followed by 50 mg daily thereafter. -
1 SUMMARY of PRODUCT CHARACTERISTICS 1. NAME of the MEDICINAL PRODUCT ANCOTIL 500 Mg, Tablet 2. QUALITATIVE and QUANTITATIVE
Flucytosine 500 mg Tablets WHOPAR part 4 March 2018 2014 (MEDA Pharma, France) HA693 Suppliers submission of the SRA approved text SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT ANCOTIL 500 mg, tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Flucytosine 500 mg Per tablet. 3. PHARMACEUTICAL FORM Tablet. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications Severe systemic fungal infections with susceptible pathogens, as an alternative or when switching from parenteral use, particularly: candidiasis, cryptococcosis, chromoblastomycosis and certain forms of aspergillosis. Combination with another antifungal agent: Flucytosine must be used in combination, in order to avoid as much as possible the selection of resistant mutations, especially in the treatment of candidiasis and cryptococcosis. Combination with amphotericin B is often synergistic and never antagonistic. 4.2. Posology and method of administration Oral use. Posology Dosages range from 100 to 200 mg/kg per day, depending on the nature of the infection, its site and sensitivity of the causative agent. The daily dosage must be divided into 3 or 4 oral doses. USE IN PATIENTS WITH RENAL IMPAIRMENT Doses must be administered at longer intervals, according to the following dosing regimen: CREATININE CLEARANCE SINGLE DOSE INTERVAL ≥ 40 mL/min 25 to 50 mg/kg 6 hours 20≤Cl<40 mL/min 25 to 50 mg/kg 12 hours 10≤Cl<20 mL/min 25 to 50 mg/kg 24 hours Cl < 10 mL/min Single dose of 25 mg/kg, then plasma monitoring 12 hours after the initial dose, before repeating the dose. PATIENTS ON DIALYSIS Since flucytosine is dialysable, the dose of this medicinal product must be repeated after each blood‐cleansing session.